Charles Gaulin
Medical Oncology · Lebanon, NHNPI 1558724013
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,214 of the $19,780 with a category attached, or 76.9%. 18 manufacturers reported payments, led by Gilead at 55.5% of the total. 2025 is the largest year on record at $13,125, more than ten times the $696 reported in 2021.
Across 49 payments — averaging $403.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$11K
- ADC Therapeutics America, Inc.$2K
- Genmab U.S., Inc.$2K
- Sanofi$2K
- Sobi, Inc$517
- GSK$341
- plus $2K from 12 others
What the payments were for
- Consulting fees$15,21477%
- Travel & lodging$1,1466%
- Food & beverage$3,32017%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 12 | $10,972 |
| ADC Therapeutics America, Inc. | 1 | $2,400 |
| Genmab U.S., Inc. | 4 | $2,004 |
| Sanofi | 5 | $1,889 |
| Sobi, Inc | 5 | $517 |
| GSK | 3 | $341 |
| Incyte Corporation | 3 | $326 |
| Beigene USA, Inc. | 4 | $250 |
| E.r. Squibb & Sons, L.L.C. | 3 | $227 |
| Beone Medicines USA, Inc. | 1 | $149 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $121 |
| Pfizer | 1 | $115 |
| Astellas Pharma US Inc | 1 | $100 |
| AstraZeneca | 1 | $100 |
| Bayer | 1 | $96 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| Bristol Myers Squibb | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,780 in reported general payments places this provider in the 80th percentile of 20 medical oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Lebanon
- Peter KaufmanLebanon$651K
- James RigasLebanon$251K
- Tyler CurielLebanon$29K
- Linda VahdatLebanon$20K
- Tara KaufmannLebanon$656
- Hilal HachemLebanon$368
- Jacob ReibelLebanon$87
- Mary ChamberlinLebanon$70
- Gabriel BrooksLebanon$50
- Bradley ArrickLebanon$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.